GlassScriptPhysician profile
Jessica St Clair
NPI 1437638376
$3,303.96
in general payments reported to CMS, 2019-2025
27 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,305 · 2022: $508 · 2023: $468 · 2024: $655 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.05 | 2021-2025 | |
| Novo Nordisk INC | $505.76 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $414.16 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $274.73 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $219.17 | 2021-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $148.19 | 2021-2024 | Belsomra, Steglatro, Gardasil 9 |
| Lundbeck LLC | $125.67 | 2024-2025 | Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $115.81 | 2021-2025 | |
| Astellas Pharma US INC | $113.10 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $80.11 | 2021-2025 | |
| Amarin Pharma, INC. | $71.02 | 2021 | |
| Currax Pharmaceuticals LLC | $68.79 | 2021-2024 | Contrave |
| Teva Pharmaceuticals USA, INC. | $61.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $51.97 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.55 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $39.40 | 2023-2024 | Eliquis |
| Idorsia Pharmaceuticals US INC | $28.78 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $28.57 | 2023 | Xarelto |
| Dexcom, INC. | $26.50 | 2022 | |
| Axsome Therapeutics, INC. | $22.45 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $19.00 | 2024 | Gvoke Hypopen |
| Eisai INC. | $18.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2023 | Xifaxan |
| Amgen INC. | $12.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica St Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.